Report Detail

Pharma & Healthcare Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, Status and Forecast 2019-2025

  • RnM3685152
  • |
  • 20 August, 2019
  • |
  • Global
  • |
  • 93 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

PARP inhibitors are a group of pharmacological inhibitors of the enzyme polymerase ADP ribosome (PARP).They are developed for multiple indications.PARP inhibitors can enhance the efficacy of radiotherapy, alkalization agents and platinum-based chemotherapy by inhibiting DNA damage repair and promoting apoptosis of tumor cells. Parp (Poly Adp-Ribose Polymerase) inhibitors is very effective in treating solid tumors and other diseases.Such as advanced ovarian cancer, fallopian tube cancer and primary peritoneal cancer.
In 2018, the global PARP (Poly ADP-ribose Polymerase) Inhibitors market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global PARP (Poly ADP-ribose Polymerase) Inhibitors status, future forecast, growth opportunity, key market and key players. The study objectives are to present the PARP (Poly ADP-ribose Polymerase) Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
AbbVie
Pfizer
AstraZeneca
GlaxoSmithKline
Clovis Oncology
Everest Pharmaceuticals
...

Market segment by Type, the product can be split into
Olaparib
Talazoparib

Market segment by Application, split into
Ovarian Cancer
Breast Cancer
Other

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global PARP (Poly ADP-ribose Polymerase) Inhibitors status, future forecast, growth opportunity, key market and key players.
To present the PARP (Poly ADP-ribose Polymerase) Inhibitors development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of PARP (Poly ADP-ribose Polymerase) Inhibitors are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.


Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Olaparib
      • 1.4.3 Talazoparib
    • 1.5 Market by Application
      • 1.5.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share by Application (2019-2025)
      • 1.5.2 Ovarian Cancer
      • 1.5.3 Breast Cancer
      • 1.5.4 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size
    • 2.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Growth Trends by Regions
      • 2.2.1 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Regions (2019-2025)
      • 2.2.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by by Players
      • 3.1.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue by by Players (2014-2019)
      • 3.1.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Concentration Ratio (CR5 and HHI)
    • 3.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players Head office and Area Served
    • 3.3 Key Players PARP (Poly ADP-ribose Polymerase) Inhibitors Product/Solution/Service
    • 3.4 Date of Enter into PARP (Poly ADP-ribose Polymerase) Inhibitors Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type (2014-2019)
    • 4.2 Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2014-2019)
    • 5.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players in North America
    • 5.3 North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type
    • 5.4 North America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application

    6 Europe

    • 6.1 Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2014-2019)
    • 6.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players in Europe
    • 6.3 Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type
    • 6.4 Europe PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application

    7 China

    • 7.1 China PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2014-2019)
    • 7.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players in China
    • 7.3 China PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type
    • 7.4 China PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application

    8 Japan

    • 8.1 Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2014-2019)
    • 8.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players in Japan
    • 8.3 Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type
    • 8.4 Japan PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2014-2019)
    • 9.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players in Southeast Asia
    • 9.3 Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type
    • 9.4 Southeast Asia PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application

    10 India

    • 10.1 India PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2014-2019)
    • 10.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players in India
    • 10.3 India PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type
    • 10.4 India PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application

    11 Central & South America

    • 11.1 Central & South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size (2014-2019)
    • 11.2 PARP (Poly ADP-ribose Polymerase) Inhibitors Key Players in Central & South America
    • 11.3 Central & South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Type
    • 11.4 Central & South America PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size by Application

    12 International Players Profiles

    • 12.1 AbbVie
      • 12.1.1 AbbVie Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
      • 12.1.4 AbbVie Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2014-2019))
      • 12.1.5 AbbVie Recent Development
    • 12.2 Pfizer
      • 12.2.1 Pfizer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
      • 12.2.4 Pfizer Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2014-2019)
      • 12.2.5 Pfizer Recent Development
    • 12.3 AstraZeneca
      • 12.3.1 AstraZeneca Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
      • 12.3.4 AstraZeneca Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2014-2019)
      • 12.3.5 AstraZeneca Recent Development
    • 12.4 GlaxoSmithKline
      • 12.4.1 GlaxoSmithKline Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
      • 12.4.4 GlaxoSmithKline Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2014-2019)
      • 12.4.5 GlaxoSmithKline Recent Development
    • 12.5 Clovis Oncology
      • 12.5.1 Clovis Oncology Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
      • 12.5.4 Clovis Oncology Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2014-2019)
      • 12.5.5 Clovis Oncology Recent Development
    • 12.6 Everest Pharmaceuticals
      • 12.6.1 Everest Pharmaceuticals Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 PARP (Poly ADP-ribose Polymerase) Inhibitors Introduction
      • 12.6.4 Everest Pharmaceuticals Revenue in PARP (Poly ADP-ribose Polymerase) Inhibitors Business (2014-2019)
      • 12.6.5 Everest Pharmaceuticals Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Summary:
      Get latest Market Research Reports on PARP (Poly ADP-ribose Polymerase) Inhibitors. Industry analysis & Market Report on PARP (Poly ADP-ribose Polymerase) Inhibitors is a syndicated market report, published as Global PARP (Poly ADP-ribose Polymerase) Inhibitors Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of PARP (Poly ADP-ribose Polymerase) Inhibitors market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

      Last updated on

      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,900.00
      $5,850.00
      $7,800.00
      3,108.30
      4,662.45
      6,216.60
      3,638.70
      5,458.05
      7,277.40
      609,414.00
      914,121.00
      1,218,828.00
      325,533.00
      488,299.50
      651,066.00
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report